Skip to main content

Krishnan Suma's Form 4 filing

Krystal Biotech, Inc. (KRYS) · filed Mar 6, 2026

Accession no.
0001298711-26-000004
Filed
Mar 6, 2026
Trade date
Mar 4, 2026
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 10 non-derivative transactions and 0 derivative transactions. Open-market sales total $6.58M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Krishnan SumaCIK 0001298711Director, Officer (President, R&D), 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 4, 2026Common StockSSaleDisposed−407$257.32−$104,729.241,427,748Direct
Mar 4, 2026Common StockSSaleDisposed−589$258.54−$152,280.061,427,159Direct
Mar 4, 2026Common StockSSaleDisposed−668$259.61−$173,419.481,426,491Direct
Mar 4, 2026Common StockSSaleDisposed−3,667$260.37−$954,776.791,422,824Direct
Mar 4, 2026Common StockSSaleDisposed−2,931$261.41−$766,192.711,419,893Direct
Mar 4, 2026Common StockSSaleDisposed−1,938$262.35−$508,434.31,417,955Direct
Mar 4, 2026Common StockSSaleDisposed−2,248$263.58−$592,527.841,415,707Direct
Mar 4, 2026Common StockSSaleDisposed−4,852$264.64−$1,284,033.281,410,855Direct
Mar 4, 2026Common StockSSaleDisposed−6,000$265.16−$1,590,9601,404,855Direct
Mar 4, 2026Common StockSSaleDisposed−1,700$266.42−$452,9141,403,155Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)